On Tuesday, a group of senators sent letters to five telehealth companies that offer care through direct-to-consumer portals from pharmaceutical manufacturers Pfizer and Eli Lilly, interrogating their financial relationships. The questions seek to determine whether contracts between pharma and telehealth companies could violate the federal anti-kickback statute.
